Allergy Therapeutics to take 'stepwise approach' to upcoming grass study
26th Nov 2019 14:15
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.
Read moreAllergy Therapeutics earnings set to top expectations
27th Jun 2019 10:07
(Sharecast News) - Biotechnology group Allergy Therapeutics told investors on Thursday that 2019 full-year earnings looked set to come in ahead of market expectations.
Read moreAllergy Therapeutics flags positive outcomes from recent treatment trial
20th May 2019 11:00
(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive Phase 1 safety and tolerability results of subcutaneous 'Acarovac MPL' (monophosphoryl lipid A) in patients with house dust mite-induced allergic rhinoconjunctivitis on Monday.
Read moreAllergy Therapeutics eyes 2020 start for hay fever inoculation trials
25th Apr 2019 10:01
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics will kick off phase III trials of its short-course inoculation for grass pollen-induced hay fever in the second half of 2020 following a successful round of meetings with German and American regulatory bodies.
Read moreAllergy Therapeutics shares plunge after disappointing clinical trial
18th Mar 2019 08:51
(Sharecast News) - Shares in biotechnology company Allergy Therapeutics were plunging on Monday morning, after it announced disappointing top-line results from the phase 3 clinical trial 'B301' of its new adjuvanted birch allergoid product.
Read moreAllergy Therapeutics profits rise as it spends less on R&D
6th Mar 2019 10:19
(Sharecast News) - Specialty pharmaceutical group Allergy Therapeutics announced its unaudited interim results for the six months ended 31 December on Wednesday, reporting a 10.6% improvement in revenue on both a reported and constant currency basis, to £46.7m.
Read moreAllergy Therapeutics sees good first-half progress
16th Jan 2019 08:51
(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market for the six months ended 31 December on Wednesday, reporting that it was trading in line with board expectations.
Read moreAllergy Therapeutics boosted by strong German performance
27th Nov 2018 10:05
(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.
Read moreAllergy Therapeutics gets trial go-ahead in Spain
14th Feb 2017 14:46
(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to
Read moreNew broad patent strengthens Allergy Therapeutics portfolio
2nd Nov 2016 09:41
(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c
Read moreAllergy Therapeutics examines potential of adjuvant portfolio
10th Oct 2016 11:59
(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot
Read moreAllergy Therapeutics swings to FY loss on R&D spend
26th Sep 2016 14:24
(ShareCast News) - Allergy Therapeutics posted a rise in revenue for the year to the end of June but said it swung to a loss as it ramped up its spending on research and development. Revenue rose 12% from 2015 to £48.5m but the company reported a pre-tax loss of £12.1m versus a profit of £654,000 th
Read moreNumis reiterates 'buy' on Allergy Therapeutics after full year results
26th Sep 2016 09:46
(ShareCast News) - Numis reiterated a 'buy' rating and target price of 37p on Allergy Therapeutics on Monday after the company reported its full year results. Allergy reported a 19% increase in revenue at constant currency to £51.5m in the year ended 30 June as it grew market share in its main Europ
Read moreAllergy Therapeutics sees good results from Acarovac Plus
8th Jul 2016 14:02
(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics published a one-year follow up study of patients using Acarovac Plus on Friday, in the peer-review journal Immunotherapy. The AIM-traded firm's Acarovac Plus product was described as a microcrystalline tyrosine-adsorbed, house
Read moreAllergy Therapeutics raises £12m to develop peanut and dust mite treatments
17th Nov 2015 14:36
(ShareCast News) - Shares in Allergy Therapeutics fell as, despite a strong trading update, the company launched a £12m discounted fundraising to speed development of treatments for peanut allergy and house dust mites allergies. The AIM-listed company completes the institutional placing by mid-after
Read more